（文章来源：证券日报） 证券日报网讯 1月8日，通化金马在互动平台回答投资者提问时表示，公司研制的化学1类新药琥珀八氢 氨吖啶片主要用于治疗轻中度阿尔茨海默病。目前该新药已完成综合审评工作，进入最后审评环节，各 项工作进展正常。有关新药的重大信息，均会在指定信息披露媒体发布。 ...

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：公司新药进展如何了？ 通化金马（000766.SZ）1月7日在投资者互动平台表示，公司研制的化学1类新药琥珀八氢氨吖啶片主要 用于治疗轻中度阿尔茨海默病。目前该新药已完成综合审评工作，进入最后审评环节，各项工作进展正 常。有关新药的重大信息，均会在指定信息披露媒体发布，请投资者关注公司公告。 ...

正是由于琥珀八氢氨吖啶片让通化金马拥有了创新药概念，因此其相关进展情况也备受机构投资者关 注。 通化金马(000766)12月15日披露的投资者关系活动记录表显示，公司于近日接待了申万宏源证券和建信 基金的调研。 通化金马主要从事医药产品的研发、生产与销售，公司目前形成了本部、圣泰生物、永康制药和源首生 物等组成的业务单元集群。公司及子公司产品涵盖抗肿瘤、微生物、心脑血管、清热解毒、消化系统、 骨骼肌肉系统、妇科系统、神经系统等多个领域。 此前，通化金马曾于2024年8月29日晚公告，公司于近日收到国家药品监督管理局签发的琥珀八氢氨吖 啶片上市申请的《受理通知书》。琥珀八氢氨吖啶片是具备完全自主知识产权的小分子化学I.I类国家级 新药，用于治疗轻中度阿尔茨海默病，于2007年11月获得I期临床试验批件，2015年8月获得III期临床试 验批件，并于2017年8月至2023年9月完成Ⅲ期临床试验并揭盲。 通化金马在2025年半年报中介绍，目前公司正严格按照国家药品监督管理局药品审评中心有关法律、法 规及指导原则开展新药上市申请相关工作。 "当前，琥珀八氢氨吖啶片已经完成专业审评的各项工作，正在进行最终的综合审评 ...

通化金马药业集团股份有限公司 投资者关系活动记录表 | | 专业队伍，打造创新营销模式，保证公司在新药销售的主 | | --- | --- | | | 导性、可控性，充分平衡药品的利润空间和患者可及性， | | | 做好新药上市的定价工作；结合市场的广泛需求，制定精 | | | 准营销策略。同时，现有生产体系已做好充分准备，设计 | | | 产能可满足阿尔茨海默病患者的用药需求，确保新药获批 | | | 后能够快速投入市场，为广大患者提供新的优质治疗选 | | | 择。 | | 关于本次活动是否涉 | 否 | | 及应披露重大信息的 | | | 说明 | | | 活动过程中所使用的 | 无 | | 演示文稿、提供的文 | | | 档等附件（如有，可 | | | 作为附件） | | | 投资者关系活动类别 | √特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他（请文字说明其他活动内容） 申万宏源证券：张静含、仰佳佳 | | | 建信基金：马牧青 | | | 上市公司： | | 活动参与人 ...

通化金马（000766.SZ）12月11日在投资者互动平台表示，我公司研制的化学1类新药琥珀八氢氨吖啶 片，已完成各项专业审评工作，进入了综合审评环节，各项审评工作正常进行中。有关新药的重大信 息，均会在指定信息披露媒体发布，请投资者关注公司公告。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：你好董秘 ，最近新药审核进度怎么样了？ ...

Core Viewpoint - Tonghua Golden Horse (000766) has announced that its chemical Class 1 new drug, Amber Dihydroaminoacridine Tablets, has completed all professional review work and has entered the comprehensive review stage, with all review processes proceeding normally [1] Group 1 - The company has responded to investor inquiries on November 26 regarding the progress of its new drug [1] - The company emphasizes that any significant information regarding the new drug will be disclosed through designated information disclosure media, urging investors to pay attention to company announcements [1]

Group 1 - The company has completed all professional review work for its innovative Class 1 drug and has entered the comprehensive review stage, indicating it is nearing approval [2] - The specific drug in question is the chemical Class 1 new drug, Amber Dihydroaminoacridine Tablets, which is currently undergoing normal review processes [2] - The company will disclose relevant information about the new drug according to regulations and requirements, urging investors to pay attention to company announcements [2]

Core Viewpoint - The company is advancing its innovative drug, Succinyl-8-hydroxyl-aminocarbazole tablets, aimed at treating Alzheimer's disease, which is expected to support its strategic goals of Asianization of traditional Chinese medicine and internationalization of chemical drugs [1]. Group 1 - The company has completed all professional review work for the new chemical drug and is currently in the comprehensive review phase, with all evaluations proceeding normally [1]. - The company plans to continue its deep layout in the neurological product pipeline and platform construction [1]. - Relevant information regarding the new drug will be disclosed according to regulations and requirements, and investors are encouraged to pay attention to company announcements [1].

Core Viewpoint - Tonghua Jinma (000766) is advancing its research on a new chemical drug, Amber Dihydroaminoacridine Tablets, aimed at treating mild to moderate Alzheimer's disease, with the review process currently in the comprehensive evaluation stage [1] Group 1 - The new drug has completed all professional review work and is now in the comprehensive evaluation phase [1] - The company will disclose any information that meets the disclosure standards as per relevant regulations [1]

Core Viewpoint - The company has developed a new chemical drug, Amber Tetrahydroaminoacridine Tablets, aimed at treating mild to moderate Alzheimer's disease, and it is currently in the comprehensive review stage after completing all professional evaluation work [1]. Group 1 - The new drug is classified as a Class 1 chemical new drug [1]. - The company assures that it will disclose any information that meets the disclosure standards as per relevant regulations [1]. - The review process for the new drug is progressing normally [1].